Home Dermatology PDF: Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature

image of woman applying cream on her arm with psoriasis

Article

PDF: Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature

Name: PDF: Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature
Price: 1.99 USD
Availability: InStock

$1.99

PDF Download: The addition of biologics that target IL-23p19 (Risankizumab) to our therapeutic armamentarium has succeeded in improving outcomes in patients with moderate-to-severe plaque psoriasis.

Category: Dermatology

PDF: Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature

Related products

PDF: Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature

PDF: Tildrakizumab for Moderate-to-Severe Plaque Psoriasis

PDF: A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis

PDF: A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis